Overproduction of Large VLDL Particles is Driven by Increased Liver Fat Content in Man

Overview

Journal Diabetologia

Specialty Endocrinology

Date 2006 Feb 8

PMID 16463046

Citations 231

Authors

M Adiels

M-R Taskinen

C Packard

M J Caslake

A Soro-Paavonen

J Westerbacka

S Vehkavaara

A Hakkinen

S-O Olofsson

H Yki-Jarvinen

J Boren

Affiliations

Soon will be listed here.

Abstract

Aims/hypothesis: We determined whether hepatic fat content and plasma adiponectin concentration regulate VLDL(1) production.

Methods: A multicompartment model was used to simultaneously determine the kinetic parameters of triglycerides (TGs) and apolipoprotein B (ApoB) in VLDL(1) and VLDL(2) after a bolus of [(2)H(3)]leucine and [(2)H(5)]glycerol in ten men with type 2 diabetes and in 18 non-diabetic men. Liver fat content was determined by proton spectroscopy and intra-abdominal fat content by MRI.

Results: Univariate regression analysis showed that liver fat content, intra-abdominal fat volume, plasma glucose, insulin and HOMA-IR (homeostasis model assessment of insulin resistance) correlated with VLDL(1) TG and ApoB production. However, only liver fat and plasma glucose were significant in multiple regression models, emphasising the critical role of substrate fluxes and lipid availability in the liver as the driving force for overproduction of VLDL(1) in subjects with type 2 diabetes. Despite negative correlations with fasting TG levels, liver fat content, and VLDL(1) TG and ApoB pool sizes, adiponectin was not linked to VLDL(1) TG or ApoB production and thus was not a predictor of VLDL(1) production. However, adiponectin correlated negatively with the removal rates of VLDL(1) TG and ApoB.

Conclusions/interpretation: We propose that the metabolic effect of insulin resistance, partly mediated by depressed plasma adiponectin levels, increases fatty acid flux from adipose tissue to the liver and induces the accumulation of fat in the liver. Elevated plasma glucose can further increase hepatic fat content through multiple pathways, resulting in overproduction of VLDL(1) particles and leading to the characteristic dyslipidaemia associated with type 2 diabetes.

Citing Articles

Clinical significance of small dense low-density lipoprotein cholesterol measurement in type 2 diabetes.

Hirano T J Diabetes Investig. 2025; 16(3):370-383.

PMID: 39778086 PMC: 11871407. DOI: 10.1111/jdi.14398.

Diverting hepatic lipid fluxes with lifestyles revision and pharmacological interventions as a strategy to tackle steatotic liver disease (SLD) and hepatocellular carcinoma (HCC).

Misceo D, Mocciaro G, DAmore S, Vacca M Nutr Metab (Lond). 2024; 21(1):112.

PMID: 39716321 PMC: 11668039. DOI: 10.1186/s12986-024-00871-3.

ANGPTL3 as a target for treating lipid disorders in type 2 diabetes patients.

Chen J, Luo Q, Yi Y, Wang J, Chen P, Luo F Lipids Health Dis. 2024; 23(1):356.

PMID: 39487451 PMC: 11528995. DOI: 10.1186/s12944-024-02352-1.

Semaglutide Treatment Effects on Liver Fat Content in Obese Subjects with Metabolic-Associated Steatotic Liver Disease (MASLD).

Dusilova T, Kovar J, Lankova I, Thieme L, Hubackova M, Sedivy P J Clin Med. 2024; 13(20).

PMID: 39458050 PMC: 11508983. DOI: 10.3390/jcm13206100.

Association of liver multi-parameter quantitative metrics determined by dual-layer spectral detector computed tomography (SDCT) with coronary plaque scores.

Wang M, Ma Y, Lan Y, Bai R, Yang L, Hou Y Quant Imaging Med Surg. 2024; 14(10):7392-7405.

PMID: 39429605 PMC: 11485365. DOI: 10.21037/qims-24-53.

References

Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S . Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med. 2002; 8(11):1288-95. DOI: 10.1038/nm788. View

Au W, Kung H, Lin M . Regulation of microsomal triglyceride transfer protein gene by insulin in HepG2 cells: roles of MAPKerk and MAPKp38. Diabetes. 2003; 52(5):1073-80. DOI: 10.2337/diabetes.52.5.1073. View

Rashid S, Watanabe T, Sakaue T, Lewis G . Mechanisms of HDL lowering in insulin resistant, hypertriglyceridemic states: the combined effect of HDL triglyceride enrichment and elevated hepatic lipase activity. Clin Biochem. 2003; 36(6):421-9. DOI: 10.1016/s0009-9120(03)00078-x. View

Boden G . Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes. 1997; 46(1):3-10. View

Donnelly K, Smith C, Schwarzenberg S, Jessurun J, Boldt M, Parks E . Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest. 2005; 115(5):1343-51. PMC: 1087172. DOI: 10.1172/JCI23621. View

Schwarz J, Linfoot P, Dare D, Aghajanian K . Hepatic de novo lipogenesis in normoinsulinemic and hyperinsulinemic subjects consuming high-fat, low-carbohydrate and low-fat, high-carbohydrate isoenergetic diets. Am J Clin Nutr. 2002; 77(1):43-50. DOI: 10.1093/ajcn/77.1.43. View

Tamura S, Shimomura I . Contribution of adipose tissue and de novo lipogenesis to nonalcoholic fatty liver disease. J Clin Invest. 2005; 115(5):1139-42. PMC: 1087181. DOI: 10.1172/JCI24930. View

Shimabukuro M, Higa N, Asahi T, Oshiro Y, Takasu N, Tagawa T . Hypoadiponectinemia is closely linked to endothelial dysfunction in man. J Clin Endocrinol Metab. 2003; 88(7):3236-40. DOI: 10.1210/jc.2002-021883. View

Cote M, Mauriege P, Bergeron J, Almeras N, Tremblay A, Lemieux I . Adiponectinemia in visceral obesity: impact on glucose tolerance and plasma lipoprotein and lipid levels in men. J Clin Endocrinol Metab. 2004; 90(3):1434-9. DOI: 10.1210/jc.2004-1711. View

10.

Wallace T, Levy J, Matthews D . Use and abuse of HOMA modeling. Diabetes Care. 2004; 27(6):1487-95. DOI: 10.2337/diacare.27.6.1487. View

11.

Pellme F, Smith U, Funahashi T, Matsuzawa Y, Brekke H, Wiklund O . Circulating adiponectin levels are reduced in nonobese but insulin-resistant first-degree relatives of type 2 diabetic patients. Diabetes. 2003; 52(5):1182-6. DOI: 10.2337/diabetes.52.5.1182. View

12.

Vozarova B, Stefan N, Lindsay R, Saremi A, Pratley R, Bogardus C . High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes. Diabetes. 2002; 51(6):1889-95. DOI: 10.2337/diabetes.51.6.1889. View

13.

Ng T, Watts G, Farvid M, Chan D, Barrett P . Adipocytokines and VLDL metabolism: independent regulatory effects of adiponectin, insulin resistance, and fat compartments on VLDL apolipoprotein B-100 kinetics?. Diabetes. 2005; 54(3):795-802. DOI: 10.2337/diabetes.54.3.795. View

14.

Westerbacka J, Corner A, Tiikkainen M, Tamminen M, Vehkavaara S, Hakkinen A . Women and men have similar amounts of liver and intra-abdominal fat, despite more subcutaneous fat in women: implications for sex differences in markers of cardiovascular risk. Diabetologia. 2004; 47(8):1360-9. DOI: 10.1007/s00125-004-1460-1. View

15.

Adiels M, Boren J, Caslake M, Stewart P, Soro A, Westerbacka J . Overproduction of VLDL1 driven by hyperglycemia is a dominant feature of diabetic dyslipidemia. Arterioscler Thromb Vasc Biol. 2005; 25(8):1697-703. DOI: 10.1161/01.ATV.0000172689.53992.25. View

16.

Bavenholm P, Pigon J, Ostenson C, Efendic S . Insulin sensitivity of suppression of endogenous glucose production is the single most important determinant of glucose tolerance. Diabetes. 2001; 50(6):1449-54. DOI: 10.2337/diabetes.50.6.1449. View

17.

Brown A, Wiggins D, Gibbons G . Glucose phosphorylation is essential for the turnover of neutral lipid and the second stage assembly of triacylglycerol-rich ApoB-containing lipoproteins in primary hepatocyte cultures. Arterioscler Thromb Vasc Biol. 1999; 19(2):321-9. DOI: 10.1161/01.atv.19.2.321. View

18.

Nieves D, Cnop M, Retzlaff B, Walden C, Brunzell J, Knopp R . The atherogenic lipoprotein profile associated with obesity and insulin resistance is largely attributable to intra-abdominal fat. Diabetes. 2002; 52(1):172-9. DOI: 10.2337/diabetes.52.1.172. View

19.

Vakkilainen J, Jauhiainen M, Ylitalo K, Nuotio I, Viikari J, Ehnholm C . LDL particle size in familial combined hyperlipidemia: effects of serum lipids, lipoprotein-modifying enzymes, and lipid transfer proteins. J Lipid Res. 2002; 43(4):598-603. View

20.

Brown A, Gibbons G . Insulin inhibits the maturation phase of VLDL assembly via a phosphoinositide 3-kinase-mediated event. Arterioscler Thromb Vasc Biol. 2001; 21(10):1656-61. DOI: 10.1161/hq1001.096640. View